Kidney Disease Clinical Trials

Showing 3841-3860 of 3,902 trials

Safety and Tolerability of Enteric-Coated Mycophenolate Sodium (EC-MPS) in Renal Transplant Patients With GI Intolerance

NCT00150020

The aim of this study is to evaluate the safety and tolerability of EC-MPS in maintenance renal transplant patients who experience gastrointestinal (GI) intolerance due to adverse events associated with mycophenolate mofetil (MMF) and were converted to EC-MPS.

Renal Transplantation

Novartis728 participantsStarted Oct 2004

East Hanover, New Jersey, United States

COMPLETEDPhase 1/2

Combination of Capecitabine and GTI-2040 in the Treatment of Renal Cell Carcinoma

NCT00056173

This phase II, 43 patient trial, will evaluate the efficacy of GTI-2040, an antisense oligonucleotide complementary to the R2 component of ribonucleotide reductase (RNR) mRNA, in combination with capecitabine, in the setting of advanced/metastatic renal cell carcinoma. Preclinical studies have shown synergy between GTI-2040 and capecitabine against renal cell carcinoma.

Carcinoma, Renal CellMetastases, Neoplasm

Aptose Biosciences Inc.43 participantsStarted Mar 2002

Concord, California, United States • Los Angeles, California, United States • Torrance, California, United States +7 more locations

TERMINATEDPhase 1/2

A Study Combining Treatment With Temsirolimus and Sunitinib for Subjects With Advanced Renal Cell Carcinoma

NCT00417677

This study is being conducted to determine the Maximum Tolerated Dose (MTD) and efficacy of the combined treatment of Temsirolimus and Sunitinib for the treatment of Advanced Kidney Cancer

Renal Cell Carcinoma

Wyeth is now a wholly owned subsidiary of Pfizer124 participantsStarted Mar 2007

Baltimore, Maryland, United States • Boston, Massachusetts, United States • New York, New York, United States +1 more locations

Safety and Tolerability of Enteric-Coated Mycophenolate Sodium (EC-MPS) in Renal Transplant Patients With GI Intolerance

Combination of Capecitabine and GTI-2040 in the Treatment of Renal Cell Carcinoma

A Study Combining Treatment With Temsirolimus and Sunitinib for Subjects With Advanced Renal Cell Carcinoma

Related Searches

Optimalization of Nephroprotection Using Atorvastatin (Sortis)

Optimalization of Nephroprotection Using N-Acetylcysteine

The Use of Drugs to Improve Kidney Function in Patients With Liver and Kidney Dysfunction

Collection of Blood and Urine Specimens From Volunteers Utilizing Health Examination Services

Adrenal Insufficiency in Critical Emergencies in Digestive Diseases

Nutrient Levels Alter Transplant Outcome

Isolated ACTH Deficiency in Patients With Hashimoto Thyroiditis

Effects of On-Line Hemodiafiltration(HDF) on Vascular Health in Chronic Hemodialysis Patients

Optimalization of Nephroprotection Using Agents Inhibiting Renin-Angiotensin-Aldosterone System

Metabolic Pattern of Cyclosporine A and Acute Renal Failure

Association Between Rosiglitazone Use and Clinical Course of Diabetic Nephropathy: Population-Based Study

Ganciclovir Pharmacokinetics in Patients Undergoing Continuous Renal Replacement Therapy

Intracellular and Renal/Myocardial Tissue Concentrations of Cyclosporine A (CsA) and Rejection Frequency Following Transplantation

Dalteparin's Influence on Renally Compromised: Anti-Ten-A Study (DIRECT)

Renal Function Optimization With Mycophenolate Mofetil (MMF) Immunosuppressor Regimes (ALHAMBRA)

Doxazosin Effects on ABPM in Hypertensive Patients With Diabetic Nephropathy

Six Months DHEA Treatment in Female Adrenal Failure